← Leaderboards
Richard A Robison
Brigham Young University
$1,085,328
Attributed
$5,426,638
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2015–19$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$5,426,638 · 1
By mechanism
R01$5,426,638 · 1
Top collaborators
- Aaron R. Hawkins5 shared
- William G Pitt5 shared
- Holger Schmidt5 shared
- Adam Thomas Woolley5 shared
Most similar at Brigham Young University
Same institution · by research overlap
- William G Pitt$1,917,929
- Adam Thomas Woolley$5,211,274
Others in their field
Top investigators on “Diagnostic Assay”
- Leonard Freedman · Leidos Biomedical Research, Inc.$250,183,724
- Ralph Parchment · Leidos Biomedical Research, Inc.$159,723,588
- David R. Weir · University Of Michigan At Ann Arbor$148,909,559
- David Heimbrook · Leidos Biomedical Research, Inc.$115,279,061
- Lynn Briscoe · Leidos Biomedical Research, Inc.$96,280,471
- Sharon L Hillier · Magee-Women'S Hospital Of Upmc$84,429,832
Research focus
Diagnostic AssayAntibiotic ResistanceBacteremiaAntibioticsAntimicrobialBacterial ResistanceBaseBloodBacteriaBlood FiltrationBlood SpecimenBacterial InfectionsCarbapenemaseCarbapenem-Resistant EnterobacteriaceaeCellsCessation Of LifeComplexCytolysisBlood CirculationDesignDetectionDevicesDiagnosisDiagnostic Procedure
Grant awards (5)
Multiplexed, Non-Amplified, Nucleic Acid-Based Identification of Multidrug Resistant Pathogens Using an Integrated Optofluidic Platform$982,407
R01 · FY2019 · AI
Multiplexed, Non-Amplified, Nucleic Acid-Based Identification of Multidrug Resistant Pathogens Using an Integrated Optofluidic Platform$988,510
R01 · FY2018 · AI
Multiplexed, Non-Amplified, Nucleic Acid-Based Identification of Multidrug Resistant Pathogens Using an Integrated Optofluidic Platform$1,002,828
R01 · FY2017 · AI
Multiplexed, Non-Amplified, Nucleic Acid-Based Identification of Multidrug Resistant Pathogens Using an Integrated Optofluidic Platform$1,069,803
R01 · FY2016 · AI
Multiplexed, Non-Amplified, Nucleic Acid-Based Identification of Multidrug Resistant Pathogens Using an Integrated Optofluidic Platform$1,383,090
R01 · FY2015 · AI